| 644 |
Bulky DNA adducts leading to chromosomal aberrations and mutations |
Beckner Andersano |
BY-SA |
1879: Bulky DNA adducts, increase
|
2 AOs
|
|
|
| 450 |
Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality |
SAROJ AMAR |
BY-SA |
12: Acetylcholinesterase (AchE) Inhibition
|
2 AOs
|
|
|
| 405 |
Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function |
SAROJ AMAR |
BY-SA |
12: Acetylcholinesterase (AchE) Inhibition
|
402: Cognitive function, decreased
|
|
|
| 236 |
Serotonin 1A Receptor Agonism leading to Anti-depressant Activity via Ca Channel Inhibition |
Timothy Allen |
BY-SA |
1431: Serotonin 1A Receptor Agonism
|
1432: Anti-depressant Activity
|
|
|
| 235 |
Serotonin 1A Receptor Agonism leading to Anti-depressant Activity via K Channel Opening |
Timothy Allen |
BY-SA |
1431: Serotonin 1A Receptor Agonism
|
1432: Anti-depressant Activity
|
|
|
| 234 |
Mu Opioid Receptor Agonism leading to Analgesia via Ca Channel Inhibition |
Timothy Allen |
BY-SA |
1425: Mu Opioid Receptor Agonism
|
1428: Analgesia
|
|
|
| 233 |
Mu Opioid Receptor Agonism leading to Analgesia via K Channel Opening |
Timothy Allen |
BY-SA |
1425: Mu Opioid Receptor Agonism
|
1428: Analgesia
|
|
|
| 443 |
DNA damage and mutations leading to Metastatic Breast Cancer |
Usha Adiga |
BY-SA |
1669: Increased, DNA damage and mutation
|
1982: metastatic breast cancer
|
Under Development |
1.103 |